CNTB vs PYPD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CNTB Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Connect Biopharma Holdings Limited Ordinary Shares (CNTB) driven by superior Valuation, Growth & Margin while PYPD counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CNTB trades at 0.8x Forward P/E with -2384.5% operating margin (+5666.7% YoY revenue) versus PYPD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against PYPD sits in BREAKOUT (12th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CNTB | PYPD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $42.6M | $132.2M | Larger Scale | PYPD |
| Trailing P/E Ratio Valuation | 0.8x | N/M | Lower Multiple | CNTB |
| Forward P/E Ratio Valuation | 0.8x | N/M | Lower Multiple | CNTB |
| Revenue Growth (YoY) Growth | +5666.7% | +0.0% | Higher Growth | CNTB |
| Operating Margin (TTM) Profitability | -2384.5% | 0.0% | Higher Margin | PYPD |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -140.5% | -243.6% | Higher ROE | CNTB |
| 52-Week Range Position Momentum | 1% ($1โ$4) | 82% ($4โ$7) | Stronger Trend | PYPD |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 68% Vol | 0.88ฮฒ ยท 59% Vol | Lower Realized Risk | PYPD |
| Unified Institutional Score Composite Signal | 41.0 / 100 (SELL) | 31.1 / 100 (SELL) | Higher Composite | CNTB |